Objective: We have previously described the generation of coxsackievirus and adenovirus receptor (aCAR)-targeted vector, and shown that intramuscular delivery in mouse leg muscles resulted in specific retrograde transduction of lumbar-motor neurons (MNs). Here, we utilized the aCAR-targeted vector to investigate the in vivo neuroprotective effects of lentivirally expressed IGF-1 for inducing neuronal survival and ameliorating the neuropathology and behavioral phenotypes of the SOD1 G93A mouse model of ALS. Methods: We produced cell factories of IGF-1 expressing lentiviral vectors (LVs) bearing aCAR or Vesicular Stomatitis Virus glycoprotein (VSV-G) on their surface so as to compare neuroprotection from MN transduced versus muscle transduced cells. We performed intramuscular delivery of either aCAR IGF-1 or VSVG IGF-1 LVs into key muscles of SOD1 G93A mice prior to disease onset at day 28. Motor performance, coordination and gait analysis were assessed weekly. Results: We observed substantial therapeutic efficacy only with the aCAR IGF-1 LV pretreatment with up to 50% extension of survival compared to controls. aCAR IGF-1 LV-treated animals retained muscle tone and had better motor performance during their prolonged survival. Histological analysis of spinal cord samples at end-stage further confirmed that aCAR IGF-1 LV treatment delays disease onset by increasing MN survival compared with age-matched controls. Intrastriatal injection of aCAR eGFP LV in rats leads to transduction of neurons and glia locally and neurons in olfactory bulb distally. Interpretation: Our data are indicative of the efficacy of the aCAR IGF-1 LV in this model and support its candidacy for early noninvasive neuroprotective therapy in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating adultonset progressive neurodegenerative disorder, characterized by the combined degeneration of upper and lower motor neurons that reside in the spinal cord, brain stem, and cortex. Affected individuals die 2-5 years following diagnosis.
1 ALS cases are mainly sporadic (SALS) and only 10% exhibit an autosomal dominant mode of inheritance (familial ALS or FALS). 2 One-fifth of FALS cases are caused by mutations in the Cu/Zn superoxide dismutase-1 (SOD1) gene. 3 Transgenic mice that overexpress the mutant human SOD1 protein (various mutants with G93A being the most aggressive) have been derived and predominantly used as models of disease. These mice develop a severe and progressive motor impairment leading to hind limb paralysis resembling ALS pathology in humans. 4 The IGF-1 family of growth factors (somatomedins) includes three structurally related ligands (IGF-1, IGF-2 and insulin), their respective receptors, and at least six IGF-1 binding proteins (IGFBP). 5 They are produced in multiple cells and exert different physiological roles by binding to distinct tyrosine kinase receptors and activating multiple downstream signaling cascades. 6 Insulin-like growth factor 1 (IGF-1 or somatomedin C) has been shown to interact with IGF-1R and can induce pleiotropic effects, including neuroprotective ones, by inhibiting apoptosis. 7 The majority of circulating IGF-1 is bound and sequestered by IGFBPs, thus extending its half-life, and controlling its distribution/bioavailability in various tissues.
Gene delivery of neurotrophic molecules, including IGF-1, shown to have a therapeutic effect on MN survival, could be a possible gene therapy strategy for ALS. 8, 9 In recent years, many studies have focused on gene delivery of growth factors to the central nervous system (CNS) in order to slow disease progression in animal models of ALS utilizing the intramuscular, [10] [11] [12] [13] intracerebral, 14, 15 intracerebroventricular 16 , and intraspinal 17, 18 routes of administration. Despite the encouraging results of these studies, subcutaneous delivery of recombinant human insulin-like growth factor 1 IGF-1 (rhIGF-1) in ALS patients had little effect in 3 clinical trials. [19] [20] [21] Each of these approaches has its own limitations which may negate achieving efficacy in ALS patients. Thus, it is clear that there is an urgent need to develop new therapeutic strategies that could enhance translatability for ALS patients.
We aimed at overcoming the limitations of existing strategies for noninvasive CNS delivery, by engineering HIV-1 vectors with tropism to spinal cord MNs delivered via the neuromuscular junction (NMJ). 22 We have previously described the generation of HIV-1-based coxsackievirus and adenovirus receptor (aCAR)-targeted vector, and shown that intramuscular (i.m.) delivery of aCARtargeted vector in mouse leg muscles results in specific retrograde transduction of lumbar MNs. 22 Our approach is based on antibody mediated cell-specific targeting and involves modification of the viral vector surface to redirect target specificity. 23 More specifically, a binding-deficient version of the a-virus Sindbis glycoprotein is used to pseudotype lentiviral vectors and to mediate fusion of viral and endosomal membrane, while the specificity is determined by an antibody (here the aCAR) chosen to recognize a specific surface receptor of the desired cell type. 23, 24 In this study, we used the aCAR-targeted LV to deliver therapeutics to SOD1 G93A ALS mice. We chose the human class I IGF-1 which has previously been reported to prolong survival in transgenic mouse ALS models upon retrograde delivery from the muscle to spinal cord MNs. 12 Utilizing the aCAR-targeted LV, we investigated in vivo the neuroprotective effects of lentivirally expressed IGF-1 for inducing neuronal survival and delaying neuropathology and behavioral phenotypes associated with the SOD1 G93A mouse model of ALS. Upon i.m. delivery, prior to onset of disease (day 28), aCAR IGF-1 LV is retrogradely transported through the synapse via the axon to the nucleus of spinal MNs, where the secreted IGF-1 can act in an autocrine manner on IGF-1 receptors on MNs to induce neuroprotective downstream signaling and/or in a paracrine on other cells. We demonstrate substantial therapeutic efficacy in vivo with aCAR IGF-1 LV pretreatment which is linked to improved motor performance. Finally, histological analysis of spinal cord samples at end point shows that i.m. delivery of aCAR IGF-1 LV delays disease onset and increases motor neuron survival compared with age-matched controls. This vector exhibits cross-species transduction in the rat CNS.
Methods and Materials
Production of LVs HEK 293T cells, obtained from ATCC, were maintained in a 5% CO 2 environment in Dulbecco's modified Eagle's medium (Sigma, UK), with 10% Newborn Calf Serum (Heat Inactivated, Sigma, Dorset, UK), 1% Penicillin/ Streptomycin and 1% L-glutamine (Sigma, UK). A total of 6 9 10 8 cells 293T cells were seeded onto a cell factory with 10 layers CF-10 (VWR, Leicestershire, UK). A DNA plasmid manufacturing company (Plasmid Factory, Bielefeld, Germany) was used for production of research grade supercoiled DNA. The complementary DNA for human insulin-like growth factor-1 (IGF-1) was encoding the Class 1 IGF-1Ea 12 was codon optimized for human and synthesized by Gene Art (Life Sciences, Paisley, UK). Thereafter, 24 h upon seeding 293T cells at 80% confluence were transfected with 0.6 mg vector plasmid (pRRLsincppt-CMV-IGF-1-WPRE), 0.3 mg of each of the packaging vector plasmids expressing the HIV-1 gag/pol gene (pMD2-LgpRRE), HIV-1 Rev (pRSV-Rev) (kindly provided by Professor James Uney, University of Bristol, Bristol, UK) together with 0.3 mg of each of paIgab, pSINmu and paCAR described in 22 following the addition of 2.5 mol/L CaCl 2 . For VSVG IGF-1, LVs cells were transfected with 0.6 mg therapeutic vector plasmid (pRRLsincppt-CMV-IGF-1-WPRE), 0.6 mg of the packaging vector plasmid pMD2-LgpRRE, 0.12 mg of the packaging vector plasmid pRSV-Rev, and 0.3 mg the VSV-G envelope plasmids (pMD2-VSV-G). Then the 16 h posttransfection medium was replaced with fresh low serum (2%) media supplemented with 10 mmol/L sodium butyrate; 72 h posttransfection, the viral supernatant was collected and filtered through a 0.20-lm-pore size filter. Preparations were concentrated by centrifugation at 6000 rpm for 12-16 h at 4°C (Beckman Coulter Avanti J-E, F500 rotor, Beckman Coulter, High Wycombe, UK). The pellet was resuspended in ice-cold phosphate-buffered saline (PBS), and was further concentrated by ultracentrifugation for 90 min at 20,000 rpm, 10°C (Beckman Coulter Optima L-80XP). The pellet was resuspended in 300 lL ice-cold TSSM formulation buffer (20 Tromethamine, 100 mmol/L NaCl, 10 mg/mL sucrose and 10 mg/mL mannitol) (2000-fold concentration). Viral titer was determined as described before. 22 
Single plasmid transfections
Single plasmid lipofectamine transfections were performed utilizing the Lipofectamine LTX and Plus Reagent kit (Life Technologies, Paisley, UK). Briefly, 24 h prior to transfection HEK 293T cells were seeded onto 6-well plates (1 9 10 6 cells/well). Next day, an hour prior to transfection medium was replaced with low serum (2%) DMEM medium and 2.5 lg of supercoiled plasmid DNA was diluted in a mixture of OPTI-MEM solution, PLUS Reagent and LTX Reagent according to manufacturer's instructions. Transfection solution was added dropwise directly onto the cells and incubated at 37°C, 5% CO 2 for 40 h.
Western blot
For cell lysate preparation, a monolayer of packaging cells were lysed with RIPA buffer (89900, Thermo Scientific, Paisley, UK) supplemented with 19 proteinase inhibitor mixture (E1014-5KU, Thermo Scientific). Lysates were cleared by centrifuging at 15,000 rpm for 30 min at 4°C and supernatant was kept at À80°C. Prior to SDS-PAGE analysis, protein concentration in the cell lysate samples was determined by BCA (Bradford and bicinconinic Acid) Protein assay (23227, Thermo Scientific). Boiled samples in 29 SDS loading buffer were resolved on a 5-12% SDSpolyacrylamide gel (SDS-PAGE). Upon electrophoresis, the separated proteins were transferred onto a nitrocellulose membrane (Hybond-ECL, GE healthcare, Amersham, UK). The resulting blots were blocked in 5% milk solution in 19 PBS-Tween (0.1% v/v) overnight at 4°C. The next day the blots were incubated with relevant primary antibodies. To detect the HA tag, blots were incubated with anti-HA-HRP (1: 5000 in 5% milk PBS-Tween 0.1% v/v, Miltenyi Biotec) for 1.5 h at room temperature. To detect human IGF-1, membranes were incubated with goat anti-human IGF-1 (2 lg/mL in 5% milk PBS-Tween 0.1% v/v, ab106836 Abcam, Cambridge, UK) for 1.5 h at room temperature. Mouse mAb to GAPDH protein (1:1000, Santa Cruz, Heidelberg, Germany) was used as loading control. Secondary antibodies used were a 1:3000 or (in 0.5% milk PBS-Tween 0.1% v/v) of relevant HRP-linked anti-IgG, followed by detection, using ECL reagent (Pierce, Thermo Scientific).
Enzyme linked immunosorbent assay of human IGF-1
Protein from animal tissue was isolated by rapidly dissecting the tissue on ice and immediately homogenizing, using either the RIPA buffer (89900, Thermo Scientific) or the Tissue Protein Extraction Reagent (Pierce, Rockford, IL) supplemented with 19 proteinase inhibitor mixture (E1014-5KU, Thermo Scientific). Enzyme-linked immunosorbent assay for human IGF-1 was performed in duplicate, using the Duo Set ELISA kit (DY291; R&D Systems, Abingdon, UK) in combination with MSD platform (Mesoscale Diagnostics, MD, Maryland, USA). Protein homogenates were diluted 2000-fold for cells and twofold for tissue, using the assay diluent and the assays performed following the MSD recommendations.
Animals
All animal procedures were approved by the local Ethical Committee and performed in accordance with United Kingdom Animals Scientific Procedures Act (1986) and associated guidelines. All efforts were made to minimize the number of animals used and the suffering. Animals were supplied by Charles River, UK and housed under a 12 h light/dark cycle with food and water available ad libitum.
The congenic C57BL/6J Tg (SOD1 G93A)1Gur(G93A-SOD1) mice (Jackson Laboratory, Bar Harbor, ME) were used 25 and were backcrossed onto the wild-type C57BL/6 mouse background (Charles River Laboratories, Wilmington, MA) for >10 generations. A priori power analysis revealed that 12 animals per group (both males and females) was a sufficient sample size in order to detect a medium effect with 80% power. 26 Transgenic mice were genotyped according to the Jackson Laboratory protocols and were organized in subgroups of 18 (6 animals per group; (i) no treatment or mock (aCAR eGFP LV), (ii) aCAR IGF-1 LV, (iii) VSVG IGF-1 LV), and they were age matched and litter matched wherever possible. Human SOD1 G93A gene copy number was assessed 27 and remained stable across generations (Copy number 25+/-1.2 copies hSOD1 G93A ; remained stable across mice used, F3-F6). We found only one mouse with an altered SOD1 gene copy number and this mouse was removed from the study.
LV delivery
For mice injections, a total volume of 100 lL of lentiviral vector solution was delivered via single bilateral intramuscular injection (28 days of age AE 1 day) in key muscle groups (gastrocnemius muscle [GA], 20 lL; tibialis anterior muscles (TA), 15 lL; intercostal muscles 10 lL; triceps muscles 5 lL) with a micro-fine 29G insulin needle, under general anesthesia with isofluorane.
For weight, survival, rotarod, and a catwalk performance, 60 SOD1 G93A mice (aCAR IGF-1 LV: n = 24 in total, n = 12 males, n = 12 females; VSVG IGF-1 LV: n = 12 in total, n = 6 males, n = 6 females; no treatment: n = 12 in total n = 6 males, n = 6 females; aCAR eGFP LV: n = 12 in total, n = 6 males, n = 6 females) were assessed. For motor neuron counts 16 SOD1 G93A mice (aCAR IGF-1 LV: n = 8 in total, n = 4 males, n = 4 females; VSVG IGF-1: n = 8 in total, n = 4 males, n = 4 females; aCAR eGFP LV: n = 4 in total; n = 2 males, n = 2 females; no treatment: n = 4 in total; n = 2 males, n = 2 females) were assessed.
Because aCAR eGFP LV and nontreated mice had the same survival and performed equivalently on the behavioral assessments they were presented in analysis as one group named as nontreated (n = 24; n = 12 males, n = 12 females).
For intrastriatal injections in rats, in vivo application of aCAR-targeted vector and control in CNS was performed to examine the neurotropism of the lentiviral preparations. In in vivo intrastriatal applications, male Wistar rats, weighing 200-250 gr were used. Animals were placed in a stereotactic frame (Taxic-6000, World Precision Instruments, Hitchin, UK) with the nose bar set at À3.3 mm under general anesthesia. The scalp was cut and retracted to expose the skull. Craniotomy was performed by drilling directly above the target region, to expose the pial surface. One single injection was directed into the right striatum using the stereotactic coordinates relative to bregma: anteroposterior, 0.5 mm; mediolateral, 3.0 mm; dorsoventral, 5.0 mm. Animals usually received 4.0 lL of pseudotyped LV vectors with a biological titer within the scale of 1 9 10 9 TU/mL via a 32G blunt needle, using an infusion pump (UltramicropumpIII and Micro4 Controller, World Precision Instruments) at a stable flow rate of 0.2 lL/min over 20 min. Upon delivery, needle was allowed to remain on site for additional 5 min prior to slow retraction.
Behavioural and survival analysis
Behavioral assessment and all in vivo tests were carried out from 65 days of age until 150 days of age blinded to treatment. All animals were weighted weekly until they reached 110 days of age at which point they were weighted daily until end stage. Motor coordination and performance were recorded using the Ugo Basile ROTA-ROD for mice (Ugo Basile, Varese, Italy). Each weekly session consisted of three trials on the rotarod, which was set to accelerate from 5 rpm (rotations per minute), and the latency to fall was recorded in seconds. The maximum time depicting no motor impairment was defined as 300 sec. The time each mouse remained on the rod was registered. Footprint analysis was also performed every 10 days. Mouse hind-and fore-paws were covered with red and green paint, respectively, to record walking patterns during continuous locomotion, and stride length was measured. Gait analysis was also performed using the automated footprint recording Catwalk system 10.5 (Noldus Information Technology, Wageningen, The Netherlands) every 10 days. Briefly, each animal was allowed to run from one side of the glass plate to the other and a camera placed underneath the glass plate recorded the video image of each run. Survival analysis was performed using the Kaplan-Meier survival analysis. End stage was defined the point at which the animals could no longer "right" themselves within 30 sec after being placed on their back.
Perfusion and tissue processing
When mice reached the endpoint (loss of righting reflex for 30 sec), they were killed by intraperitoneal injection of 200 mg/kg of sodium pentobarbitone, and then transcardially perfused with 20 mL saline (0.9% w/v NaCl) supplemented with heparin 5 units/mL (Sigma) followed by 20 mL of 4% (w/vol) paraformaldehyde (PFA, Sigma Aldrich) in PBS. Spinal cord, TA, GA, intercostal, and triceps muscles were removed and either postfixed for 4 h in 4% PFA, followed by cryoprotection in 10% glycerol and 20% sucrose in PBS for at least 72 h or snap frozen in liquid nitrogen and stored at À80°C until further analysis. Fixed tissues were subsequently embedded and frozen in OCT (Surgipath FSC22; Leica Microsystems, Wetzlar, Germany). Twenty micrometer coronal sections from the sacral plexus through the entire lumbar and thoracic parts of the spinal cord were cut using a cryostat (Leica Microsystems), mounted on gelatinized slides, and stored at À20°C.
For western blot analysis upon euthanasia, mice were perfused with 20 mL saline (0.9% w/v NaCl) plus heparin. The same tissues, as mentioned above, were removed and snap frozen using liquid nitrogen.
Rats were killed 3 weeks postinjection by intraperitoneal injection of 200 mg/kg of sodium pentobarbitone, transcardially perfused with 200 mL saline (0.9% w/v NaCl) plus heparin, followed by 250 mL of 4% PFA in PBS. Brains were removed and postfixed for 4 h in 4% PFA, followed by cryoprotection in 10% glycerol and 20% sucrose in PBS for at least 72 h. The brain was subsequently embedded and frozen in OCT (Surgipath FSC22; Leica Microsystems).
Motor neuron quantification
Sections were processed for cresyl violet staining stain (0.1% Cresyl Fast Violet; BDH, Lutterworth, UK). Surviving motor neurons were counted in every 10th section under a light microscope at 920 magnification in order to avoid repetitive counting (n = 24 mice [eight per group]). MN counting was performed blindly between different groups and sexes. Only motor neurons with a clearly identifiable nucleus and nucleolus and a cell soma were counted. MN quantification was performed in spinal cord sections extracted from animals at end stage.
Immunohistochemisty
Immunohistochemistry was performed on slide mounted spinal cord sections. Tissue was permeabilized for 1 h with PBS-containing 10% donkey serum and 0.1% Triton-X100. Antibodies to eGFP (1:500, ab290, Abcam), ChAT (1:50 AB114P, Millipore, Watford, UK) were diluted in the same buffer and placed on sections for 72 h at 4°C. Sections were then blocked for 30 min prior to incubating for 3 h at room temperature with donkey anti-rabbit, anti-goat secondary antibodies conjugated with AlexaFluor â 488 or 594 (1:500; Invitrogen, Paisley, UK), respectively. Sections were mounted with ProLong anti-fade aqueous mounting medium (Invitrogen). For rat brain tissue, 30 lm coronal sections from the olfactory bulb (OB), through the entire striatum, globus pallidus and substantia nigra (SN) were cut using a cryostat (Leica Microsystems), mounted on poly-L-lysine coated slides, and stored at À20°C. Immunohistochemistry was performed on slide mounted brain sections. The tissue was permeabilized and blocked for 1 h with PBScontaining 10% donkey serum and 0.1% Triton-X100. Primary antibodies to eGFP (1:500, ab290, Abcam), NeuN (1:100, MAB377, Millipore) and GFAP (1:400, MAB360, Millipore) were diluted in the same buffer and applied on sections for 48 h at 4°C. Sections were then washed three times with PBS for 10 min, shaking gently and blocked for 30 min prior to incubation with secondary fluorescently labeled antibodies (for 3 h at room temperature). ProLong anti-fade aqueous mounting medium with DAPI was used to apply coverslips (Invitrogen).
Statistical analysis
Survival analysis of the SOD1 G93A mice was performed by Kaplan-Meier analysis, which generates a v 2 value to test for significance. All other tests not involved in survival analysis were performed by multi-way analysis of variance followed by a Bonferroni post hoc analysis of means differences between groups (GraphPad Prism Software, San Diego, CA).
Results

Generation of aCAR IGF-1 and control LVs
In the current study we utilized the aCAR-targeted lentiviral vector (aCAR-targeted LV) to deliver therapeutics to SOD1 G93A mice. We chose the human class I Insulin like growth factor 1 (IGF-1Ea), which has previously been reported to prolong survival in transgenic mouse ALS models through viral mediated delivery applied distally. 12, 14, 16 Towards this end we cloned a codonoptimized version of the human class 1 IGF-1 (class 1 IGF-1Ea) into an HIV-1-based lentiviral vector under the control of the human cytomegalovirus (CMV) enhancer and promoter (Fig. 1A) . We inserted an HA tag on the 5 prime end of IGF-1. As a control we used aCAR-targeted LV vector expressing the enhanced green fluorescent protein (eGFP), a system which was previously found and reconfirmed here using cell factory preparations to be effective for targeted expression in spinal cord MNs after TA injections 22 (Fig. 1A) . Human IGF-1 expression was assessed via western blot in total protein extracts following lipofectamine transfections of either the pRRLsincppt-CMV-IGF1-WPRE therapeutic or the pRRLsincppt-CMVeGFP-WPRE construct in HEK293T cells (Fig. 1B) . Human IGF-1 levels were measured in homogenates and supernatant of cells transfected with HIV-1 326-pRRLsincppt-CMV-IGF-1-WPRE and 326-pRRLsincppt-CMV-eGFP-WPRE plasmids using an enzyme-linked immunosorbent assay (ELISA) that recognized the expressed human IGF-1 (Fig. 1C) . Detectable levels of human IGF-1 were noted in both homogenates (>2 lg/lL) and supernatant (>1 lg/lL) of cells transfected with the therapeutic expression plasmid pRRLsincppt-CMV-IGF-1-WPRE. Highest levels were found in homogenates of cells transfected with pRRLsincppt-CMV-IGF-1-WPRE. Negligible levels of human IGF-1 were detected only in the lysates of cells transfected with the control 326-pRRLsincppt-CMV-eGFP-WPRE expression plasmid, with background levels detected <20 ng/lL.
To assess the expression levels of lentivirally expressed IGF-1 we infected HEK 293T cells with LVs expressing the human IGF-1 at MOI 50. Cells transduced with LVs expressing eGFP were used as control. Using an ELISA we were able to detect human IGF-1 in lysates (mean IGF-1 levels 732.14 ng/mL) and secreted IGF-1 in the supernatant of cells transduced (mean IGF-1 levels 7591.88 ng/mL) with LVs expressing the human IGF-1 (Fig. 1D) . No IGF-1 was detected in either lysates or supernatants of cells transduced with control eGFP-expressing LVs (mean background levels at 220.15 ng/mL for cell lysates).
These data demonstrate that the synthetic human IGF1-Ea we cloned in HIV-1 is efficiently expressed and secreted upon infection of HEK293T cells with IGF-1-expressing LVs.
We subsequently generated a therapeutic aCAR-targeted LV encoding the same secretable codon-optimized human IGF-1 under the same promoter. By utilizing cell factories we produced high titer preparations of therapeutic-targeted aCAR IGF-1 LVs. We also produced Vesicular Stomatitis Virus glycoprotein (VSV-G) pseudotyped LVs expressing human IGF-1 to assess neuroprotection resulting from muscle-produced IGF-1.
Intramuscular delivery of aCAR IGF-1 LV prolongs survival of SOD1
G93A animals
To investigate the neuroprotective effects of aCAR IGF-1 LV on ALS pathogenesis, we performed single bilateral delivery of either aCAR-targeted or control VSV-G pseudotyped LVs expressing IGF-1 into key muscle groups of both male and female SOD1 G93A mice (n = 24 animals/ group) predisease onset at 28 days of age (Table S1) . Impact of the different treatments on survival of SOD1 G93A mice was analyzed by Kaplan-Meier survival curves. Treated mice were monitored up to end stage and compared with control groups. Onset of disease (measured by weight loss from denervation-induced muscle atrophy) was significantly delayed by a median of 32 days in aCAR IGF-1-treated mice when compared with nontreated control mice ( Fig. 2A; P < 0.0001 Wilcoxon, signed-rank test) and by 9 days when compared with VSVG IGF-1-treated mice ( Fig. 2A ; VSVG IGF-1-treated, 141.5 days P = 0.0133, Wilcoxon signed-rank test). When male aCAR IGF-1-treated SOD1 G93A cohorts were analyzed separately disease onset was significantly delayed by 29.5 days when compared with nontreated control male mice ( Fig. S1A; 145 vs. 115.5 days P < 0.0001 Wilcoxon, signed-rank test) and by 6 days versus VSVG IGF-1-treated mice; however, the later delay was not significant. In the female cohorts, treatment with aCAR IGF-1 significantly delayed disease onset by 32.5 days when compared with nontreated control female mice ( Fig. S1 ; 153 vs. 120.5, P < 0.0001) and by 9 days when compared with VSVG IGF-1-treated mice ( Fig. S1 ; 153 vs. 144, P = 0.0087). We observed an 8-day difference in median disease onset between female and male aCAR IGF-1 LV-treated cohorts, however this difference was not significant (females: 153 days vs. males: 145 days; v 2 = 1.711, P = 0.1908). Survival analysis showed that mice treated with targeted therapeutic aCAR IGF-1 LV showed a 14-day increase in median lifespan when compared with nontreated control mice ( Fig. 2B; 169 vs. 155; log-rank test, v 2 = 18.15, P < 0.0001) and 9 days when compared with VSVG IGF-1-treated mice ( Fig. 2B; 169 vs. 160; log-rank test, v 2 = 6.308, P = 0.012). There was no difference in survival between nontreated and VSVG IGF-1-treated control mice. When male and female cohorts were analyzed separately aCAR IGF-1 LV treatment significantly increased median lifespan in both male and females when compared with nontreated control cohorts by 12 and 8 days ( Fig. S1B ; males, log-rank test, v 2 = 8.513, P = 0.0035; females v 2 = 7.913, P = 0.0049), respectively. When aCAR IGF-1 LV-treated cohorts were compared with VSVG IGF-1-treated male and female mice, median lifespan was significantly increased in both female and male mice ( Fig. S1B ; females: 7.5 days; log-rank test, v 2 = 4.756, P = 0.0292; males: 4 days; log-rank test, v 2 = 4.518, P = 0.0335). When we compared median survival between female and male aCAR IGF-1 LV-treated cohorts, we found no significant difference (females: 168 days vs. males: 170 days; log-rank test, v 2 = 0.1008, P = 0.7509). Interestingly we observed some variability in survival with two female mice surviving up to 197 and 198 days and 1 male mouse up to 240 days, which accounts for extension of survival of up to 27% and 54%, respectively, compared with VSVG IGF-1 LV and nontreated controls.
Weekly body weight measurements revealed a significantly slower loss of body weight in aCAR IGF-1-treated mice from 135 days onward. P28 aCAR IGF-1 LV-treated female mice maintained their weights when compared with age-matched controls (Fig. 2C ). More specifically, aCAR IGF-1 LV treatment significantly delayed weight decline at days 136-145 when compared to nontreated controls and at days 152 (P < 0.1) and from day 155 onwards (P < 0.001) when compared with VSVG IGF-1 LV-treated mice. In male mice aCAR IGF-1 LV treatment significantly delayed weight decline compared with nontreated male mice from day 145 (P < 0.01), but no significant effect was found versus the VSVG IGF-1 LV-treated male control mice (Fig. 2D) .
aCAR IGF-1 LV improves motor function and coordination in SOD1 G93A mice
Motor performance, coordination and gait analysis were assessed weekly from day 65 onwards, for both IGF-1-treated and control groups (Fig. 3) . SOD1G93A mice were tested weekly for rotarod coordination and their performance was analyzed over time for female (n = 12 per group) and male (n = 12 per group) cohorts (Fig. 3A) .
Rotarod tests showed that aCAR IGF-1 LV-treated female mice maintained their ability to coordinate their movement for a longer period than both VSVG IGF-1-treated improved in aCAR IGF-1 LV-treated compared with both control groups (one-way ANOVA, Tukey's Multiple Comparison Test, P < 0.05) (C) P28 aCAR IGF-1 LV-treated female mice maintained their weight compared with age-matched controls. aCAR IGF-1 LV significantly delayed weight decline compared with nontreated controls at days 136, 140-145 (**P < 0.01) and at day 160 and onwards (*P < 0.05) and compared to VSVG IGF-1 LV-treated mice at days 152 (*P < 0.05) and from d155 onward (*P < 0.05). (D) Compared to VSVG IGF-1 LV-treated male mice controls, aCAR IGF-1 LV had no effect on weight decline. aCAR IGF-1 LV significantly delayed weight decline compared to nontreated males mice from day 145 (**P < 0.01, ***P < 0.001). aCAR IGF-1 LV-treated mice (n = 24) are shown in magenta, VSVG-IGF-1 LV-treated mice (n = 12) are shown in light blue and nontreated control group in black.
and nontreated mice starting from 130 days until end stage (P < 0.05 from 130 days of age onward, n = 12 animals per group). However, aCAR IGF-1 LV-treated male mice had significantly better rotarod performance than nontreated control animals starting from 130 days onward (P < 0.05, n = 12 animals per group), but no significant difference was observed between aCAR IGF-1 LV and VSVG IGF-1 LV-treated male mice. Manual footprint analysis showed impaired walking patterns in control animals compared with aged-matched aCAR IGF-1 LV-treated mice from 115 days onwards (P < 0.05, from 115 day onward, n = 12 animals per group) (Fig. 3B) . Representative walking patterns from manual footprint analysis are presented in Figure S2B . Results were confirmed on a separate cohort of mice where digital footprint analysis also demonstrated impaired walking patterns in control animals compared with aged-matched aCAR IGF-1 LV-treated mice, but this time from 125 days onwards (Fig. 3C ).
Representative footprints of late symptomatic stage mice showed that nontreated SOD1 G93A mice dragged their hind legs, whereas aCAR IGF-1 LV-treated mice showed minor defects in coordination of steps (Fig. S2A) .
Overall, the administration of MN-targeted aCAR IGF-1 LV significantly delayed the onset of disease as assessed by rotarod performance tests, gait analysis and body weight compared with nontreated and VSVG IGF-1 LVtreated control SOD1 G93A mice. Interestingly, there was no statistical difference observed between male mice treated with aCAR IGF-1 LV and VSVG IGF-1 LV in both rotarod test and body weight assessment other than one time point at 155 days of age in body weight measurements of surviving mice (Fig. 2D ).
Intramuscular application of aCAR IGF-1 LV resulted in motor neuron protection in SOD1 G93A mice ALS has been associated with progressive and severe spinal motor neuron atrophy and cell death. 28 Targeted aCAR IGF-1 LV was assessed for its ability to exert a neuroprotective effect and consequently increase motor neuron survival in SOD1 G93A mice compared with nontreated control animals when applied preonset of disease at 28 days of age. Lumbar and thoracic regions of spinal cord were labeled and evaluated for surviving MNs at end stage. MNs were identified by their location within the spinal cord, their morphology and their size. Histological evaluation of end-stage lumbar spinal cord samples revealed loss and atrophy of MNs in nontreated mice (Fig. 4A top panel and Fig. 4B ) and VSVG IGF-1 LV compared with largesized surviving MNs observed in aCAR IGF-1 LV-treated SOD1 G93A mice (Fig. 4A lower panel) . Surviving MNs in treated animals appeared dark stained after labeling with Nissl dye, with a lighter stained nucleus and a very dark and well-defined nucleolus. Gene transfer at end-stage aCAR eGFP injected SOD1 G93A mice was assessed by confocal microscopy and was evident mainly in axons and less so in some of the remaining motor neurons of ventral horn (Fig. 4B) . To assess survival of MNs we performed total cell counts of surviving MNs in both thoracic and lumbar parts of spinal cord obtained from nontreated, VSVG IGF-1 LV and aCAR IGF-1 LV-treated animals at end-stage of the disease (both male and females). aCAR IGF-1 LV-treated animals showed a significant preservation of MNs in the lumbar part of the spinal cord compared with both nontreated and VSVG IGF-1 LV mice (mean MN counts 18.55 AE 1.22 vs. 12 AE 2.12 and 6.80 AE 1.20, respectively, P = 0.0026) (Fig. 4C) . aCAR IGF-1 LV-treated animals displayed higher numbers of surviving MNs per section compared with nontreated and VSVG IGF-1 injected mice (mean MN counts 17.43 AE 1.44 vs. 10 AE 1.12 and 6.85 AE 1.75, respectively; P = 0.018) also in the thoracic region of the spinal cord (Fig. 4C) . To determine whether survival of spinal cord MNs was due to neuroprotection derived from lentivirally expressed IGF-1 we measured the levels of human IGF-1 in homogenates of end-stage lumbar spinal cord samples from nontreated and aCAR IGF-1 LV-treated animals. Toward this end, we used an ELISA that recognized the expressed human IGF-1 and not the endogenous murine one. Detectable levels of human IGF-1 were found in the spinal cord of aCAR IGF-1 LV-treated mice (mean IGF-1 levels 18.736 ng/mg), while little to no IGF-1 was detected in nontreated animals, with mean background levels at 2.1 ng/mg (Fig. 4D) .
Cross-species neuronal transduction of aCAR LV
To further investigate the in vivo tropism of the aCARtargeted vector and investigate its ability to be retrogradely transported, aCAR-targeted and control vectors were stereotaxically applied to the rat striatum. Details of the lentiviral preparations produced for striatal injections are presented in Table S2 . Prior to the injection, vectors were normalized to vector infectivity values to ensure equal administration of potent lentiviral particles. All rats received 4 lL of appropriate lentiviral preparation diluted in formulation buffer (TSSM). Three weeks postinjection the animals were euthanized and brains were examined for eGFP expression, indicative of retrograde delivery and expression of the transgene by the HIV-1-based aCARtargeted LV. Figure S3 shows that the aCAR-targeted vector efficiently delivers the transgene to the site of injection showing considerable affinity for neurons, though still transducing a small amount of astroglia. The nontargeted control vector (lacking the targeting antibody but still pseudotyped with neurotropic sindbis-G) did also transduce neurons, however, at lower efficacy as it bears detargeting mutations. The aCAR-targeted vector resulted in retrograde transduction of mytral cells of the OB, a distal structure connected to the striatum's olfactory tubercle, as previously observed by us for other retrogradely transported vectors. 29 No significant transduction of thalamic nuclei, or pars compacta of the SN was observed though, which was probably due to the absence of vector uptake at thalamostriatal and nigrostriatal nerve terminals presumably due to the absence of aCAR receptors in those neuronal synapses.
In summary, we observed substantial therapeutic efficacy in vivo with MN-targeted aCAR IGF-1 LV pretreatment with significant delay of disease onset and extension of survival compared with both VSV-G IGF-1 LV and nontreated control animals linked to increased survival of MNs. Efficacy is linked to improved motor performance, as aCAR IGF-1 LV-treated mice retained muscle tone and motor function during their prolonged survival.
Discussion
In this study, we report proof of concept studies testing a novel-targeted LV-expressing IGF-1 for noninvasive neuroprotective gene therapy for ALS. IGF-1 is known to have a neurotrophic effect on motor neurons. 30 To date IGF-1-based therapies have little beneficial effect upon systemic or intrathecal administration in ALS patients. [19] [20] [21] The poor outcomes of these studies may possibly be due to low availability of IGF-1 as free IGF-1 is reduced while IGF-1R expression is upregulated in both the CNS and muscle of ALS patients. 31, 32 Alternative to these approaches, many studies have focused on distal targeting of MNs delivering therapeutics through the retrograde route. Indeed, IGF-1 has previously been reported to prolong survival in transgenic mouse ALS models through viral mediated delivery applied distally, 12, 14, 16 while direct spinal cord application has had poor outcomes. 17, 18 We previously showed that in vivo i.m. delivery of aCAR-targeted vector in mouse leg muscles results in specific retrograde transduction of lumbar MNs. 22 In the current study, we utilized the aCAR-targeted vector and investigated the in vivo neuroprotective effects of lentivirally expressed IGF-1 following intramuscular application to SOD1 G93A mice. Specifically, we showed that we can produce high titer preparations of aCAR-targeted LVs that efficiently express human IGF-1. Utilising ELISA we confirmed expression of human IGF-1 only in lysates and supernatant of cells transduced with LVs expressing this factor. Background levels detected were at least 5 to 20 orders of magnitude lower than therapeutic LV transduced cells, showing that synthetic human IGF1-Ea is successfully expressed and mature IGF-1 is secreted upon transduction of HEK293T cells with LVs.
The results of this study indicate that IGF-1 trophic factor delivery to CNS via a one-time i.m. application of aCAR IGF-1 LVs has significant therapeutic benefit and can modify disease progression in the SOD1 G93A mice. The advantage of our delivering strategy over existing approaches resides on high targeting specificity of the LVs applied distally which overcomes the need of direct injection into the spinal cord where the affected MNs reside. Recently a study utilising AAV encoded microRNA against human SOD1 has shown that suppressing SOD1 in MNs either by intracerebroventicular or by lumbar intrathecal injections can be neuroprotective. 33 In vivo i.m. application of our targeted therapeutic vector resulted in human IGF-1 protein expression in the spinal cord (Fig. 4) , which in turn significantly delayed disease onset and increased mean survival of SOD1 G93A mice by 14 days. Efficacy observed was linked to improved motor performance, as aCAR IGF-1 LV-treated animals retained muscle tone and motor function during their prolonged survival. Our current findings are in agreement with similar studies showing that treatment with this isoform of IGF-1 is beneficial. 11, 12 Similar to others 14, 16 we observed some variability in survival as not all cohorts of mice Figure 3 . aCAR IGF-1 LV significantly prolonged motor performance in SOD1 G93A mice. (A) SOD1G93A mice were tested weekly for rotarod coordination. The rotarod performance was analysed over time of either only females (n = 12 per group), or only males (n = 12 per group) cohorts. aCAR IGF-1 LV-treated female mice had better rotarod performance as compared with age-matched controls from 130 days onwards (two-way ANOVA, Bonferroni post hoc test, ***P < 0.001, *P < 0.05; error bars represent AE SEM). aCAR IGF-1 LV-treated male mice had better rotarod performance as compared with age-matched nontreated controls from 130 days onwards (two-way ANOVA, Bonferroni post hoc test, *P < 0.05; error bars represent AE SEM). No significant difference was observed between aCAR IGF-1 LV and VSVG IGF-1 LV-treated male mice. (B) Dynamic parameters of gait analysis using manual footprint analysis. Stride length is the distance in millimeters between successive placements of the same paw. Footprint analysis showed impaired walking patterns in control animals compared to aged-matched P28 aCAR IGF-1 LV-treated mice from 115 days onwards (data represent average values per group AE SEM (n = 6 per group); two-way ANOVA, Bonferroni post hoc test, **P < 0.01, ***P < 0.001). (C) Dynamic parameters of gait analysis using digital footprint analysis. Impaired walking patterns in control animals compared to aged-matched from 125 days onwards (data represent average values per group AE SEM (n = 6 per group); two-way ANOVA, Bonferroni post hoc test, *P < 0.05, ***P < 0.001). aCAR IGF-1 LV-treated mice (n = 24; 12 males and 12 females) are shown in magenta, VSVG IGF-1 LV-treated mice (n = 12; 6 males and 6 females) are shown in light blue and nontreated (n = 24; 12 males and 12 females) control group in black. (regardless of sex) responded equally to i.m. injection of therapeutic aCAR IGF-1 LV. More specifically, in our initial cohorts, we observed two female mice that survived up to 197 and 198 days, respectively, while in a separate cohort a male mouse survived up to 240 days which account for extension of survival of up to 27% and 54%, respectively. So far we are the first to report such a survival effect. However, when all cohorts tested were combined, mean survival was significantly extended by 14 and 9 days when compared with nontreated and VSVG IGF-1 LV-treated control cohorts, respectively. Although our sample size was sufficient to detect a medium effect with 80% power, our observations further demonstrate the necessity of including large animal numbers in order to detect meaningful therapeutic effect. 26 Variability reported in our study may be attributed to a number of factors such as: (i) the delivery strategy, as muscle injection cannot by principle be accurate as far as the injection point and depth is concerned, (2) the given dose used, as only 50% of particles injected are expected to be functional, 22 or (3) even the strength of expression of the transgene itself, which is controlled by a CMV enhancer/promoter. Thus, interpreting and comparing the results of various IGF-1 ALS studies may be challenging even when the same delivery route is chosen as other factors such as disease variability linked to the animal model or IGF-1 isoform utilized can contribute to this variability. Sex-specific differences in disease onset and progression as well as response to therapy have been reported in a number of studies. 17, 25, 34 In the current study, we found no significant difference when we compared overall disease onset and survival between male and female aCAR IGF-1 LV-treated mice. No significant difference was also observed in both cases between nontreated and VSVG IGF-1-treated control groups. To determine whether neuroprotection can result from retrogradely transported muscle-produced IGF-1 we included in our study VSVG IGF-1 LVs injected control cohorts. Interestingly, we observed differences in disease onset between the treatment groups only in male mice (Fig. 2) . Disease onset was significantly delayed in male aCAR IGF-1 LV-treated mice when compared with nontreated male mice, however this was not significant when compared with VSVG IGF-1-treated male cohort. Unlike males, in female mice, disease onset was delayed and survival was extended significantly in comparison to both control cohorts. Similar differences in body weight maintenance and motor function were observed between aCAR IGF-1 LV and VSVG IGF-1 LV-treated male cohorts (Figs. 2D and 3A) . A possible explanation for this could be that MN rescue by aCAR IGF-1 LV treatment possibly slowed muscle atrophy and consequent weight loss. However, because VSVG IGF-1 LV-treated male mice also maintained their weights, it is likely that weight was maintained in IGF-1-treated mice because IGF-1 had an anabolic effect on the injected muscles (local expression) and consequently these mice were better able to feed and perform on the rotarod.
It is known that IGF-1 has a key role both in muscle and nerve tissue anabolism and consequently locally enhances muscle and promotes neuronal survival. [35] [36] [37] The IGF-1 gene, which encodes IGF-1 undergoes alternative splicing producing multiple isoforms. One of these isoforms, the IGF-1Ea, which is used in this study, is the main supply of anabolic agent in the form of mature IGF-1 38, 39 and is produced by active muscle. 40 When provided as a muscle-specific transgene it results in muscle hypertrophy and enhances regeneration upon injury. [40] [41] [42] Several studies have reported that muscle restricted expression of muscle-specific IGF-1Ea (mIGF-1) isoforms in SOD1 G93A mice resulted in enhanced MN survival, delayed disease onset, and stabilized the NMJ. 11, 43, 44 Moreover, localized overexpression of IGF-1Ea has been shown to protect a range of different tissues, including skeletal muscle, against neurodegenerative diseases without increasing systemic IGF-1 levels. 11, 45 In a recent study, Barton and colleagues showed that viral expression of IGF-1Ea and not of mature IGF-1 promotes the hypertrophic response of muscle in vivo. 46 Thus, this can explain the effect we observe in VSVG IGF-1 LV-treated male cohorts both in body weight maintenance and rotarod performance. A CMV enhancer/ promoter is active in muscle, and upon intramuscular injection of VSVG IGF-1 LV, the expression of IGF1-Ea in transduced myofibers can have an anabolic effect on the injected muscles and consequently allow these mice to be better able to feed and have disease progression similar to the aCAR IGF-1 LV-treated ones.
It could be argued that the effect we see in these animals results from retrogradely transported muscle-produced IGF-1 having a therapeutic effect in their spinal cord MNs. However, this possibility can be excluded as VSVG IGF-1 LV injected male mice do maintain their body weight, have rotarod performance, and delayed disease onset similar to age-matched aCAR IGF-1 LV-treated males but their mean survival is not extended (Figs. 2,  S1 ). Most importantly, MN survival in VSVG IGF-1 LVinjected animals was poor compared with the enhanced MN survival observed as a result of i.m. pretreatment with aCAR IGF-1 LV (Fig. 4C) . These results strongly implicate that localized expression of IGF-1 in muscle is beneficial, possibly via a muscle enhancement mechanism but does not prolong survival.
Additionally, lack of therapeutic effect or sex-restricted efficacy was observed in studies where the human IGF1Ea isoform was overexpressed in muscle 47 or upon intraparenchymal spinal cord delivery 17 in SOD1 G93A mice. The male only effect observed in the second study could not be linked to sex-specific differences 17 according to the authors. Results from the present study demonstrate that female aCAR IGF-1 LV-treated cohorts appeared to respond better as far as disease progression is concerned, maintaining their weights and motor performance when compared with control groups. However, the extension in survival was similar in both male and female aCAR IGF-1 LV-treated mice. Additionally, MN survival and long-lasting human IGF-1 expression in the spinal cord were seen in both males and females (Fig. 4) , suggesting that the effect was unlikely related to sex-specific differences.
Unlike most of these studies where IGF-1 is directly delivered to the muscle, our therapeutic strategy resides on retrogradely transported IGF-1. Our targeted therapeutic aCAR IGF-1 LV allows delivery of IGF-1 specifically in the spinal MNs by targeting the CAR receptor at the NMJ. This way, IGF-1 can be directly delivered to the spinal cord MNs which express IGF-R, 32 and via secretion possibly establish an autocrine loop, bypassing the risk of reduced bioavailability of injected IGF-1 by IGFBP.
32
Assessment of aCAR IGF-1 LV dose escalation and application of treatment at disease onset in this and new rodent models of disease 48 will provide further information as to the extent of the therapeutic efficacy that can be achieved with this targeted therapeutic vector in ALS. Combinatorial gene therapy utilizing multicistronic LV vectors expressing additional factors, such as heat shock proteins 49 or miR-206, 50 could further enhance the potency of this approach. As the aCAR antibody expressed on the LV surface binds both mouse and human receptors 51 testing in iPSC-derived motor neurons from ALS 52 patients could be possible and might enhance translatability.
In summary, our data highlight a novel noninvasive strategy to specifically deliver therapeutics into spinal cord MNs through single distal i.m. injections, and show for the first time that the antibody-targeted therapeutic aCAR IGF-1 LV vector is beneficial in disease progression and survival in a mouse model of ALS at the given dose. We are the first to report substantial therapeutic efficacy in vivo with aCAR IGF-1 LV pretreatment where survival was extended up to 50% compared with VSVG IGF-1 LV and nontreated controls. These data support that aCAR IGF-1 LV is a promising candidate for early non-invasive neuroprotective gene therapy in ALS.
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Additional Supporting Information may be found online in the supporting information tab for this article: G93A mice, treatment with aCAR IGF-1 significantly delayed median disease onset versus both nontreated and VSVG IGF-1-treated control mice by 32.5 days 9 days (153 vs. 120.5, P < 0.0001; 153 vs. 144, P = 0.0087) , respectively. (B) Median survival of both male and female aCAR IGF-1 LV-treated mice, was significantly increased versus nontreated control cohorts by 12 and 8 days respectively (males v 2 = 8.513, P = 0.0035; females v 2 = 7.913, P = 0.0049). When compared with VSVG IGF-1-treated cohorts, aCAR IGF-1 LV treatment significantly increased median lifespan of both female (7.5 days v 2 = 4.756, P = 0.0292) and male mice (4 days; v 2 = 4.518, P = 0.0335). microscope either with a 109 objective (olfactory bulb) or 49 objective (striatum). Colour inserts were captured at site of injection with confocal microscope. Sections were triple stained, using anti-eGFP antibody shown in green, antibody to NeuN shown in red, and antibody to GFAP shown in magenta. (B) Quantification of vector tropism in the striatum. Scale bars, 50 lm. 
